Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Liminal BioSciences Inc is a biotechnology business based in the US. Liminal BioSciences shares (LMNL) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $0.42 |
|---|---|
| 52-week range | $0.37 - $2.38 |
| 50-day moving average | $0.48 |
| 200-day moving average | $0.72 |
| Wall St. target price | $1.05 |
| PE ratio | 0.7935 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.57 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.42 from 2022-09-29
| 1 week (2022-09-23) | -6.67% |
|---|---|
| 1 month (2022-09-01) | -19.23% |
| 3 months (2022-07-01) | -20.65% |
| 6 months (2022-03-30) | -58.42% |
| 1 year (2021-10-01) | -80.91% |
|---|---|
| 2 years (2020-10-01) | -96.16% |
| 3 years (2019-10-01) | 10.36 |
| 5 years (2017-09-29) | 1.2319 |
Valuing Liminal BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Liminal BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Liminal BioSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Liminal BioSciences shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $565,000 |
|---|---|
| Gross profit TTM | $-17,704,000 |
| Return on assets TTM | -35.02% |
| Return on equity TTM | -461.75% |
| Profit margin | 8610.8% |
| Book value | $0.88 |
| Market capitalisation | $14.1 million |
TTM: trailing 12 months
We're not expecting Liminal BioSciences to pay a dividend over the next 12 months.
Liminal BioSciences's shares were split on a 1:1000 basis on 5 July 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Liminal BioSciences shares – just the quantity. However, indirectly, the new 99900% higher share price could have impacted the market appetite for Liminal BioSciences shares which in turn could have impacted Liminal BioSciences's share price.
Over the last 12 months, Liminal BioSciences's shares have ranged in value from as little as $0.365 up to $2.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Liminal BioSciences's is 1.1391. This would suggest that Liminal BioSciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Liminal BioSciences Inc. , a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.